|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis B virus-induced oncogenesis显示文摘Hepatocellular carcinoma (HCC) is one of the most com- mon cancers in the world with an annual incidence of more than 500 000 in the year 2000. Its incidence is rising in many countries. Recently, it has been estimated that about 53% of HCC cases in the world are related to hepatitis B virus (HBV). The epidemiological association of HBV with HCC is well established. In recent studies, it was revealed that HBsAg carriers have a 25-37 times increased risk of developing HCC as compared to non-infected people. At present, HBV-associated carcinogenesis can be seen as a multi-factorial process that includes both direct and indirect mechanisms that might act synergistically. The integration of HBV DNA into the host genome occurs at early steps of clonal tumor expansion. The integration has been shown in a number of cases to affect a variety of cancer- related genes and to exert insertional mutagenesis. The permanent liver inflammation, induced by the immune response, resulting in a degeneration and regeneration process confers to the accumulation of critical mutations in the host genome. In addition to this, the regulatory proteins HBx and the PreS2 activators that can be encoded by the integrate exert a tumor promoter-like function resulting in positive selection of cells producing a functional regulatory protein. Gene expression profiling and proteomic techniques may help to characterize the molecular mechanisms driving HBV-associated carcino- genesis, and thus potentially identify new strategies in diagnosis and therapy. | Joachim Lupberger Eberhard Hildt | 2007 | World Journal of Gastroenterology2007，13，1： | 56 |
| 2 | Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) is one of most common malignancies in the world. Systemic treatments for HCC, particularly for advanced stages, are limited by the drug resistance phenomenon which ultimately leads to therapy failure. Recent studies have indicated an association between drug resistance and the existence of the cancer stem cells (CSCs) as tumor initiating cells. The CSCs are resistant to conventional chemotherapies and might be related to the mechanisms of the ATP Binding Cassette (ABC) transporters and alterations in the CSCs signaling pathways. Therefore, to contribute to the development of new HCC treatments, further information on the characterization of CSCs, the modulation of the ABC transporters expression and function and the signaling pathway involved in the self renewal, initiation and maintenance of the cancer are required. The combination of transporters modulators/inhibitors with molecular targeted therapies may be a potent strategy to block the tumoral progression. This review summarizes the association of CSCs, drug resistance, ABC transporters activities and changes in signaling pathways as a guide for future molecular therapy for HCC. | Caecilia HC Sukowati Natalia Rosso Lory S Crocè Claudio Tiribelli | 2010 | World Journal of Hepatology2010，2，3： | 16 |
| 3 | Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?显示文摘AIM:To evaluate the effectiveness of hepatic arterial infusion chemotherapy(HAIC) for advanced hepatocellular carcinoma(HCC) resistant to transarterial chemoembolization(TACE).METHODS:This study was conducted on 42 patients who received HAIC for advanced HCC between 2001and 2010 at our hospital.5-fluorouracil(5-FU) was administered continuously for 24 h from day 1 to day 5 every 2-4 wk via an injection reservoir.Intra-arterial cisplatin or subcutaneous interferon was administered in combination with the 5-FU.The patients enrolled in this retrospective study were divided into two groups according to whether or not they fulfilled the criteria for resistance to TACE proposed by the Japan Society of Hepatology in 2010(written in Japanese);one group of patients who did not fulfill the criteria for TACE resistance(group A,n = 23),and another group who fulfilled the criteria for TACE resistance(group B,n = 19).We compared the outcomes in terms of the response and survival rates between the two groups.RESULTS:Both the response rate and tumor suppression rate following HAIC were significantly superior in group A than in group B(response rate:48% vs 16%,P = 0.028,tumor suppression rate:87% vs 53%,P = 0.014).Furthermore,both the progression-free survival rate and survival time were significantly superior in group A than in group B(3-,6-,12-,and 24-mo = 83%,70%,29% and 20% vs 63%,42%,16% and 0%,respectively,P = 0.040,and 9.8 mo vs 6.2 mo,P = 0.040).A multivariate analysis(Cox proportional hazards regression model) showed that resistance to TACE was an independent predictor of poor survival(P = 0.007).CONCLUSION:HAIC administrating 5-FU was not effective against advanced HCC resistant to TACE.Other tools for treatment,i.e.,molecular-targeting agents may be considered for these cases. | Hiroyuki Kirikoshi Masato Yoneda Hironori Mawatari Koji Fujita Kento Imajo Shingo Kato Kaori Suzuki Noritoshi Kobayashi Kensuke Kubota Shin Maeda Atsushi Nakajima Satoru Saito | 2012 | World Journal of Gastroenterology2012，18，16： | 9 |
| 4 | 手术切除联合射频消融治疗多发性肝癌合并肝硬化显示文摘目的探讨手术切除联合射频消融(radiofrequency ablation,RFA)治疗多发性肝癌合并肝硬化的可行性及疗效。方法2003年8月-2006年1月我院收治多发性肝癌合并肝硬化18例,术前经超声、螺旋CT或MRI共发现瘤体46个。其中2个病灶10例,3个病灶6例,4个病灶2例,全麻下距瘤体2cm做包括瘤体的不规则肝段切除、次病灶RFA治疗。结果18例均顺利完成手术切除及RFA治疗。同时行胆囊切除术2例,脾切除及食管胃底周围血管离断术1例。手术切除时间(37.4±8.8)min;单个病灶RFA时间(25.6±8.9)min,总RFA时间(39.8±14.7)min;总手术时间(152.6±30.8)min;总术中出血量(465.6±171.0)ml。未出现腹腔出血、胃肠道损伤、膈肌损伤及肝功能衰竭等严重并发症。术后1个月螺旋CT增强扫描证实,18例手术切除边缘未见残余肿瘤组织,RFA治疗病灶均完全坏死。随访6—31个月,5例发现肝内新病灶。采用经皮RFA进行治疗,其中1例术后15个月死于肝内再复发及肺转移;2例分别于术后7、16个月死于肝功能衰竭。结论手术切除联合RFA治疗多发性肝癌合并肝硬化安全可行,近期治疗效果肯定,最大程度保存受损的肝功能,但应根据病灶的位置及肝功能的状况选择合适的病人进行治疗。 | 范瑞芳 柴福录 贺冠宪 卫立辛 李红梅 解娅莉 | 2007 | 中国微创外科杂志2007，7，1： | 7 |
| 5 | 调节性T细胞在肝细胞肝癌中的表达及化疗与免疫治疗对其表达的影响显示文摘肝细胞肝癌(以下简称肝癌)是最常见的恶性肿瘤之一。据卫生部统计,我国肝癌年病死率为20.40/10万[1],严重威胁人民的健康和生命安全。肝癌患者由于免疫功能低下,机体免疫防御反应不能有效进行是肝癌产生免疫逃逸、容易转移复发的重要因素。 | 肖琦 蔡军 肖建生 | 2011 | 南昌大学学报(医学版)2011，51，5： | 7 |
| 6 | The role and clinical implications of microRNAs in hepatocellular carcinoma显示文摘Hepatocellular carcinoma (HCC) is common and one of the most aggressive of all human cancers. Recent studies have indicated that miRNAs, a class of small noncoding RNAs that regulate gene expression post-transcriptionally, directly contribute to HCC by targeting many critical regulatory genes. Several miRNAs are involved in hepatitis B or hepatitis C virus replication and virus-induced changes, whereas others participate in multiple intracellular signaling pathways that modulate apoptosis, cell cycle checkpoints, and growth-factor-stimulated responses. When disturbed, these pathways appear to result in malignant transformation and ultimately HCC development. Recently, miRNAs circulating in the blood have acted as possible early diagnostic markers for HCC. These miRNA also could serve as indicators with respect to drug efficacy and be prognostic in HCC patients. Such biomarkers would assist stratification of HCC patients and help direct personalized therapy. Here, we summarize recent advances regarding the role of miRNAs in HCC development and progression. Our expectation is that these and ongoing studies will contribute to the understanding of the multiple roles of these small noncoding RNAs in liver tumorigenesis. | ZHAO Xue YANG Zhen LI GuangBing LI DongKai ZHAO Yi WU Yan ROBSON Simon C. HE Lian XU YiYao MIAO R-uoYu ZHAO HaiTao | 2012 | Science China(Life Sciences)2012，55，10： | 6 |
| 7 | 四种常见血清肝酶在乙型肝炎相关性肝癌中的表达及意义显示文摘目的通过前瞻性的研究四种常规检测血清肝酶与乙型肝炎相关性肝癌的风险关系,为临床诊断提供参考依据。方法前瞻性的收集2008年6月-2013年6月294例在医院治疗乙型肝炎患者临床资料,评估四种常规检测的肝酶(丙氨酸氨基转移酶[ALT],天门冬氨酸氨基转移酶[AST],碱性磷酸酶[ALP]和γ-谷氨酰胺转肽酶[GGT])与患者临床病理特征之间的关系,通过Kaplan-Meier和logistic方法分析四种肝酶的基线水平对乙型肝炎相关性肝癌发生的预测价值。结果调查294例患者中有26例在随访时间结束时发展成了肝癌,肝癌发生率为8.8%;在4种肝酶中,GGT和ALP是乙型肝炎相关性肝癌发生独立危险因素,基于ALP和GGT构建的AG模型能够有效的预测乙型肝炎患者发生肝癌的风险。结论血清GGT和ALP是乙型肝炎患者肝癌的发生预测因素。 | 陈国梁 项美姣 张家敏 倪德生 胡胜军 严秋亮 何湛 | 2017 | 中华医院感染学杂志2017，27，3： | 6 |
| 8 | 肝癌动物模型研究进展显示文摘在世界范围内肝癌位居恶性肿瘤发病率的第五位,是导致癌症相关死亡的第二大疾病[1]。肝癌易复发和转移,预后效果差,研究表明,肝癌患者肝切除术后5年存活率仅为30%~40%[2]。肝癌的发生是一个多阶段逐步演变恶化的过程。与肝癌发生相关的危险因素包括病毒感染~[3]、化学致癌物接触~[4]、酗酒~[5]等,因此,研究如何提高肝癌诊断,加强预防和改进治疗措施至关重要。 | 王冠文 杨爽 张全胜 | 2016 | 实用器官移植电子杂志2016，4，2： | 5 |
| 9 | Apaf-1基因在肝细胞肝癌中的表达和意义显示文摘目的 探讨凋亡蛋白活化因子1(apoptoic protease-activating factor 1,Apaf-1)基因mRNA及其蛋白在肝细胞肝癌(HCC)中的表达和意义.方法 采用逆转录-聚合酶联反应(RT-PCR)和免疫组化(SP)的方法 检测手术切除53例肝癌组织,53例癌旁组织和14例肝血管瘤组织中的Apaf-1基因mRNA及其蛋白的表达情况,同时结合临床病理资料分析其在肝细胞癌中发生、发展的意义.结果 在癌组织中Apaf-1基因mRNA及蛋白的表达率明显降低(分别为45.28%,32.07%),低于癌旁组织(90.56%,79.24%)和肝血管瘤组织(100%,92.85%),差异有统计学意义(P<0.05);而癌旁组织和肝血管瘤组织之间的差异无统计学意义.且Apaf-1基因蛋白的表达缺失与患者的HBsAg、Edmondsor分级和有无门静脉癌栓有关,而与患者性别、肿瘤直径和AFP水平无关.结论 Apaf-1基因的表达异常可能对人HCC的发生和发展起着重要作用,可能对临床诊治和判断患者的预后有一定的参考意义. | 董明明 易继林 杨志芳 刘谨文 殷茜 沈文状 龚文平 | 2010 | 临床外科杂志2010，18，9： | 4 |
| 10 | Celecoxib enhances the detoxification of diethylnitrosamine in rat liver cancer显示文摘AIM:To study the effect of celecoxib(CXB) on diethylnitrosamine activation through the regulation of cytochrome P450 in a hepatocarcinogenesis model.METHODS:Six-week-old male Sprague-Dawley rats were randomly divided into fi ve groups,a non-treated group(NT) ,a diethylnitrosamine-treated group(DEN) ,a DEN+CXB-treated group(DEN+CXB) ,and CXB 8 d-treated and CXB 32 d-treated groups.The effects of celecoxib on the enzymatic activities of CYP1A1,2A,2B1/2,and 2E1 were assessed in hepatic microsomes 24 h after DEN administration.Changes in CYP1A1 and CYP2B1/2 protein expression were also evaluated.The rate of DEN metabolism was measured by the production of the deethylation metabolite acetaldehyde,and the denitrosation metabolite nitrite.RESULTS:DEN+CXB administration produced a significant increase in the enzymatic activities of CYP2B1/2 and 1A1,whereas it did not change the activities of CYP2A and 2E1,compared to that of the DEN group.CXB treatment for eight days did not produce a signif icant effect on enzymatic activity when compared to the NT group;however,when it was administered for prolonged times(CXB 32 d group) ,the enzymatic activities were increased in a similar pattern to those in the DEN+CXB group.The observed increase in the enzymatic activities in the DEN+CXB group was accompanied by an increase in the CYP2B1/2 protein levels;no changes were observed in the levels of CYP1A1.In vitro,CXB increased the denitrosation of DEN,a pathway of metabolic detoxification.The addition of SKF-525A,a preferential inhibitor of CYP2B,abrogated the denitrosation of DEN.CONCLUSION:These results suggest that the mechanism of action of CXB involves enhancement of the detoxif ication of DEN by an increasing denitrosation via CYP2B1/2. | Martha Estela Salcido-Neyoy Adolfo Sierra-Santoyo Olga Beltrán-Ramírez José Roberto Macías-Pérez Saúl Villa-Trevio | 2009 | World Journal of Gastroenterology2009，15，19： | 3 |
| 11 | MicroRNA-26a靶向高迁移率族蛋白A2抗体对肝癌细胞增殖及迁移的影响显示文摘目的探讨miRNA-26a(miR-26a)作用于靶向基因HMGA2在肝癌细胞增殖及迁移中的作用及其机制。方法收集2018年9月至2019年9月经温州市中医院病理证实的肝癌组织标本(n=30)及其癌旁正常组织标本(n=30)。将miR-26a模拟物、对照模拟物(miR-Control)、HMGA2 siRNA或阴性对照siRNA(Control)转染人肝癌细胞株HepG2或Huh-7细胞。采用逆转录-定量聚合酶链反应(RT-qPCR)检测miR-26a在肝癌组织中的表达情况。采用MTT试验和划痕试验测定细胞增殖和迁移能力。采用RT-qPCR和Western blot检测miR-26a与高迁移率组AT-hook 2(HMGA2)mRNA的表达情况。通过生物信息和荧光素酶报告基因分析miR-26a与HMGA2 mRNA的作用关系。结果RT-qPCR结果显示,肝癌组织miR-26a表达水平为(0.11±0.02),较正常组织样本表达量的(0.25±0.03)明显降低(t=21.268,P<0.05);Ⅲ+Ⅳ期miR-26a表达水平为(0.05±0.01),明显低于Ⅰ+Ⅱ期miR-26a表达水平的(0.09±0.01)(t=15.491,P<0.05)。细胞实验表明,miR-26a组在Huh-7[(3.10±0.30),(4.10±0.40)]和HepG2[(3.08±0.31),(4.11±0.40)]细胞中,相比于对照组[(3.90±0.40),(5.50±0.60);(3.92±0.41),(5.49±0.58)]增殖能力降低(t=8.764、10.634,11.148、10.728,均P<0.05),迁移能力[(0.50±0.06),(0.65±0.07)]相比于对照组[(1.00±0.10),(0.96±0.10)]同样明显降低(t=23.483、13.910,均P<0.05)。生物信息学和体外实验表明,HMGA2是miR-26a的直接靶点。恢复miR-26a模拟转染细胞中HMGA2的表达,相比miR-26a组[(0.24±0.02),(0.31±0.03);(0.45±0.05)],可明显逆转miR-26a对肿瘤细胞增殖和迁移的抑制作用[(0.31±0.03),(0.40±0.04);(0.93±0.08)](t=10.634、9.859、27.868,均P<0.05)。结论miR-26a通过直接靶向HMGA2抑制肝癌细胞的增殖和迁移。miR-26a异常降低及其靶点HMGA2升高可能是参与肝癌发生、发展的重要因素。 | 金若珏 刘三海 黄强 吴春明 周光伟 | 2021 | 中国基层医药2021，28，10： | 3 |
| 12 | 体素内不相干运动成像评价大鼠肝细胞癌的微血管生成显示文摘目的探讨应用体素内不相干运动成像(intravoxel incoherent motion diffusion weighted imaging,IVIM)评估肝细胞癌(hepatocellular carcinoma,HCC)的微血管密度(microvessel density,MVD)及微血管侵犯(microvascular invasion,MVI)的可行性。方法建立大鼠HCC模型,应用IVIM序列扫描大鼠,选取IVIM图像所对应的HCC病灶行病理学检查,测定其MVD,并判断病灶中是否发生MVI。采用Spearman相关分析评估表观弥散系数(apparent diffusion coefficient,ADC)、IVIM参数(D、D*及f)与HCC病灶MVD的相关性,采用独立样本t检验比较MVI阳性(+)组、阴性(–)组的ADC及IVIM参数。结果共纳入50个HCC病灶,ADC、D与MVD呈负相关(r=–0.406,P=0.003;r=–0.468,P=0.001),D*、f与MVD无统计学相关性(P=0.172、0.074);MVI(+)组和MVI(–)组的ADC及IVIM参数(D、D*及f)差异无统计学意义(P=0.393、0.395、0.221、0.550)。结论 ADC及IVIM参数(D)可用于评估HCC病灶MVD,但其评估MVI的能力受限。 | 李谋 郑兴菊 黄子星 宋彬 | 2018 | 华西医学2018，33，4： | 2 |
| 13 | 术前碘油栓塞对原发性肝癌消融率的影响显示文摘目的:探讨术前碘油栓塞对射频消融治疗原发性肝癌(primary hepatic carcinoma,PHC)消融率的影响.方法:回顾性分析85例PHC患者,接受经导管肝动脉栓塞术(hepatic arterial embolization,TAE)联合经皮射频消融术(radiofrequency ablation,RFA)治疗的患者为A组(TAE联合RFA组),共45例;单纯接受RFA治疗的患者为B组(单纯RFA组),共40例.对比两组患者的首次肿瘤消融率,分析术前碘油栓塞是否能有效提高肿瘤完全消融率,减少肿瘤组织残留.采用SPSS19.0统计学软件对数据资料进行处理.结果:A组患者术后肿瘤病灶完全消融率84.4%,高于B组(57.5%),机会残留率8.9%,低于B组(35.0%),差异均有统计学意义(P<0.05),而两组间肿瘤部分残留率差异无统计学意义(P>0.05);对于直径≤3 c m的单发肿瘤,A组首次完全消融率93.3%(14/15),B组为92.3%(12/13)(P>0.05);而对于多发和/或直径介于3-5 cm的肿瘤,A组完全消融率80.0%(24/30),明显高于B组40.7%(11/27)(P<0.05).结论:术前碘油栓塞对直径≤3 cm的单发肿瘤无助于提高肿瘤完全消融率,而对>3 cm的单发肿瘤或多发肿瘤则有助于提高肿瘤完全消融率. | 孙兴伟 靳勇 白旭明 程龙 顾星石 原强 荆剑 | 2015 | 世界华人消化杂志2015，23，36： | 2 |
| 14 | 健脾活血祛湿方经AQP9和线粒体细胞凋亡途径对H22肝癌荷瘤裸鼠的影响显示文摘目的观察健脾活血祛湿方对H22肝癌皮下移植瘤裸鼠的影响,探讨其是否通过干预水通道蛋白9(AQP9)蛋白靶点调控肝癌细胞线粒体凋亡途径,从而发挥抗肿瘤的可能机制。方法采用H22肝癌细胞成功建立裸鼠皮下移植瘤模型,选取成瘤裸鼠25只随机分为空白组(生理盐水灌胃,0.2 ml/10 g)、阳性对照组(环磷酰胺腹腔注射,30 mg/kg)和健脾活血祛湿方低、中、高剂量组(灌胃,25、50、100 mg/kg),每组5只,1次/d。计算各组H22肝癌移植瘤裸鼠的抑瘤率及脾脏指数,采用荧光探针JC-1和流式细胞术检测线粒体膜电位(ΔΨm)的变化;Western blot检测瘤组织B细胞淋巴瘤/白血病-2(Bcl-2)、B淋巴细胞瘤因子相关X蛋白(Bax)的表达变化;免疫组织化学检测AQP9表达。结果与空白组相比,阳性对照组裸鼠的生存状态较差,瘤体体积减小,抑瘤率、Bcl-2、Bax蛋白表达显著增高(P<0.05,P<0.01),脾指数、线粒体膜电位水平显著降低(P<0.01);免疫组织化学结果显示AQP9表达增多。与阳性对照组相比,健脾活血祛湿方高剂量组瘤体体积减小,瘤重和抑瘤率均无明显变化(P>0.05),脾指数升高(P<0.05),线粒体膜电位显著降低(P<0.05),Bcl-2、Bax表达和Bax/Bcl-2比值显著增高(P<0.05);免疫组织化学结果显示AQP9广泛表达,呈现AQP9棕褐色深染,部分细胞出现胞核的形态改变,细胞空泡显著增多。结论健脾活血祛湿方在一定剂量下对H22肝癌荷瘤裸鼠有明显的抑瘤作用,并可改善裸鼠免疫功能,其作用可能与调控AQP9干预肝癌细胞线粒体凋亡途径有关。 | 李嘉 高玲 陈晓兰 杨孝芳 蒲翔 张雄 | 2020 | 中国临床研究2020，33，8： | 2 |
| 15 | GTP结合蛋白4在肝癌中的表达及作用的初步研究显示文摘目的:探讨GTP结合蛋白4(GTP binding protein 4,GTPBP4)在肝癌(hepatocelluar carcinoma,HCC)组织中的表达及沉默GTPBP4对人肝癌Hep G2细胞增殖和周期影响。方法:收集南昌大学第二附属医院2014年3月至2015年2月24例新鲜临床HCC组织及配对癌旁组织标本,采用Western blot检测GTPBP4在组织中的表达差异;在Hep G2细胞中用慢病毒介导的RNAi干扰技术沉默该基因,运用荧光显微镜观察感染效率,Western blot、RT-q PCR检测沉默效果;CCK-8实验、流式细胞仪观察细胞增殖、细胞周期变化。结果:1)Western blot结果显示GTPBP4在21例(87.5%)HCC组织标本中明显高表达(P<0.000 1);2)用荧光显微镜观察显示慢病毒成功感染Hep G2细胞后,发现90%细胞表达GFP;LV-GTPBP4-RNAi组GTPBP4在RNA水平、蛋白水平较对照组分别下降约70%和67%;3)GTPBP4基因沉默96 h后,LV-GTPBP4-RNAi组增殖能力抑制,抑制率约54.51%;LV-GTPBP4-RNAi组G0/G1期增多,S期减少,细胞周期发生停滞。结论:GTPBP4在HCC组织中高表达,利用RNAi干扰GTPBP4基因表达后,人肝癌Hep G2细胞增殖能力明显下降,细胞周期停滞于G0/G1期,但是具体分子机制不明。 | 刘茂生 郑燕 吴水梅 李腾政 钟思思 郭武华 谢正元 | 2016 | 中国肿瘤临床2016，43，24： | 2 |
| 16 | Implantation of a drug delivery system during surgery for patients with primary hepatocarcinoma显示文摘BACKGROUND: Postoperative regional chemotherapy is one of the most effective methods to decrease the recurrent rate and improve the prognosis of primary hepatocarcinoma (PHC). This study was undertaken to assess the optimal pathway to implant the drug delivery system (DDS) in the different ways of resecting PHC so as to offer a valuable reference to clinical implantation of the DDS. METHODS: One hundred and ninety cases were divided into two groups according to whether the tumors were resected completely (A) or not (B). Groups A and B were subdivided into three groups a, b and c according to the pathway selected for DDS implantation. The patients in subgroup a received DDS implantation through both the hepatic artery and portal vein (A+P-implanted group), the patients in subgroup b received DDS implantation through the portal vein (P-implanted group), and the patients in subgroup c received DDS implantation through the hepatic artery (A-implanted group). RESULTS: The 1- and 3-year recurrent rates of subgroup c in group A were higher than those of subgroup b, and there was no significant difference between subgroups a and b. Compared with subgroups a and c, the 1- and 3-year survival rates of subgroup b were similar to those of group a but higher than those of group c. The 1- and 3-year survival rates between subgroups a and b in group B were significantly different. The prognosis of subgroup c was lower than that of subgroup a and no significant difference was observed between subgroups b and c. CONCLUSIONS: The DDS should be implanted into the portal vein when PHC is resected completely. It may be better to implant it into both portal vein and hepatic artery if the tumor cannot be completely resected. | Wan-Ping Chen, Xin He, Qi-Fa Ye and Ke Li Institute of Organ Transplantation, Third Xiangya Hospital, Xiangya Medical College, Central South University, Changsha 410013, China, and Institute of Clinical Pharmacology, Xiangya Medical College, Central South University, Changsha 410078, China | 2006 | Hepatobiliary & Pancreatic Diseases International2006，5，3： | 2 |
| 17 | Novel Tumor-associated Antigen of Hepatocellular Carcinoma Defined by Monoclonal Antibody E4-65显示文摘单音的同种细胞的抗体, E4-65,由与 SMMC-7721cells 使老鼠免疫生产了,一根人的 hepatocellular 癌(HCC ) 房间线,被用来识别并且描绘 anunreported 联系 HCC 的抗原。间接免疫荧光研究证明那 E4-65 抗体从八根 HCC 房间线与五,然而并非与 10 根 non-HCC 肿瘤房间线或一根正常的肝房间线反应了。用免疫组织化学的检查, E4-65 抗原在房间膜上并且在人的肝肿瘤纸巾的细胞质被检测,但是没在大多数另外的肿瘤,或正常成年或胎儿的纸巾被发现,除了在消化系统的纸巾的弱积极的反应。蛋白质印迹分析证明那 E4-65 抗体在人的 HCCcell 线和织物 lysates 跳了到 45 kDa 蛋白质。酶处理并且凝集素弄污没在 E4-65 抗原检测糖类链。这联系 HCC 的蛋白质代表一个潜在地有用的目标为诊断并且人的 HCC 的免疫疗法。 | Ke ZOU Jihang JU Hong XIE | 2007 | Acta Biochimica et Biophysica Sinica2007，39，5： | 1 |
| 18 | 肝脏恶性肿瘤区域化疗研究进展显示文摘肝脏区域化疗即在肝脏局部灌注化疗药物,是晚期肝癌首选的治疗方法。肝动脉灌注及肝脏隔离灌注是肝脏区域化疗的主要方式,各有其优势及局限性,在实验及临床研究中仍在发展改进。肝脏区域化疗灌注途径选择及药物应用方面的认识在不断深化。高温低氧灌注及生物化学治疗在肝脏区域化疗中的应用更是拓展了肝癌化疗的思路,将其带入了一个新境界。肝癌细胞耐药性是肝脏区域化疗面临的挑战及研究的热点,解决这一难题是提高化疗疗效的关键。 | 刘鑫 曹喜才 | 2010 | 国际医学放射学杂志2010，33，6： | 1 |
| 19 | 腹腔镜射频消融治疗多病灶肝癌的疗效及安全性显示文摘目的:探讨腹腔镜射频消融(radiofrequency ablation,RFA)治疗多病灶肝癌的可行性、安全性及疗效。方法:2001年10月-2005年8月,我院对15例多病灶肝癌患者在全麻下进行治疗。其中男12例,女3例,平均(51.5±9.0)岁。术前经超声、螺旋CT或MRI发现瘤体36个,其中2个病灶11例,3个病灶2例,4个病灶2例。肿瘤平均直径(3.1±1.1)cm。乙型肝炎13例,丙型肝炎2例。合并肝硬化13例,胆囊结石2例。结果:15例均顺利完成手术,同时行胆囊切除术2例。单个病灶RFA平均时间(30.2±13.3)min,平均总手术时间(98.7±28.5)min,平均总出血量(145.3±82.8)ml。未出现腹腔出血、胃肠道损伤、膈肌损伤及肝功能衰竭等严重并发症。术后1个月螺旋CT增强扫描证实,病灶完全坏死率达100%。随访12-52个月(平均35个月),1例发现肝内新病灶,3例消融部位复发,均采用经皮射频消融进行治疗。3例分别在术后24、28、36个月死于肝内复发及肝功能衰竭。结论:腹腔镜RFA治疗多病灶肝癌安全可行,近期疗效肯定,最大程度保存了受损的肝功能。但应选择肿瘤位于肝脏表面、肝左外叶或邻近胆囊的病例进行治疗。 | 范瑞芳 柴福录 贺冠宪 白明东 上官建营 李红梅 解娅莉 | 2007 | 腹腔镜外科杂志2007，12，1： | 1 |
| 20 | Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib显示文摘Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Prognosis and treatment options are stage dependent. In general, prognosis of patients with unresectable HCC is poor, especially for those patients with impaired liver function. Whereas treatment with the novel molecular tyrosine kinase inhibitor sorafenib (Nexavar) was shown to result in prolonged survival in patients with preserved liver function, its' possible application in HCC-patients with strongly impaired liver function has not been clearly assessed. Here, we report on a 47-year-old male patient who presented with Child-Pugh class C liver cirrhosis and multifocal, non-resectable HCC. The patient was treated for 27 mo with Sorafenib, which was not associated with major drug-related side effects. During treatment, a reduction in tumour size of 24% was achieved, as assessed by regular CT scan. Moreover,within the 27 mo interval of stable tumour disease, liver function improved from Child-Pugh class C to class A. | Christoph Roderburg Jhenee Bubenzer Michael Spannbauer Nicole do O Andreas Mahnken Tom Luedde Christian Trautwein Jens JW Tischendorf | 2010 | World Journal of Hepatology2010，2，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员